Recombinant MVA viruses expressing HIV env, gag and pol modified HIV clade A / G, clade B, and clade C genes

摘要

A pharmaceutical composition comprising a recombinant MVA virus expressing an HIV env, gag-pol or modified gene thereof for the production of an HIV Env, Gag-Pol antigen by expression from said recombinant MVA virus, where it is modified said HIV env gene to encode an HIV Env protein composed of gp120 and the transmembrane and ectodomain domain of gp41 but lacking part or all of the cytoplasmic domain of gp41, and a pharmaceutically acceptable carrier; wherein said env gene, HIV gag-pol or modified gene thereof is taken from the clade AG and said HIV env gene or modified gene thereof is at least 97% identical to the sequence set forth in Figure 12, and said HIV gag-pol gene or modified gene thereof is at least 97% identical to the sequence set forth in Figure 13, and wherein the pol gene encodes an asparagine in amino acid 185 of the reverse transcriptase, a threonine in the amino acid 266 of reverse transcriptase and a glutamine in amino acid 478 of reverse transcriptase; or said env, gag-pol HIV or modified gene thereof is taken from clade B and said HIV env gene or modified gene thereof is at least 97% identical to the sequence set forth in Figure 23, and said gene HIV gag-pol or modified gene thereof is at least 97% identical to the sequence set forth in Figure 24, and wherein the pol gene encodes an asparagine in amino acid 185 of the reverse transcriptase, a threonine in amino acid 266 of reverse transcriptase and a glutamine in amino acid 478 of reverse transcriptase; or said env, gag-pol or modified gene thereof is taken from clade C and said HIV env or modified gene thereof is at least 97% identical to the sequence set forth in Figure 39, and said gene HIV gag-pol or modified gene thereof is at least 97% identical to the sequence set forth in Figure 40, and wherein the pol gene encodes an asparagine in amino acid 185 of the reverse transcriptase, a threonine in amino acid 266 of reverse transcriptase and a glutamine in amino acid 478 of reverse transcriptase; wherein said env gene is inserted into deletion II of the MVA virus and said gag-pol gene is inserted into deletion III of the MVA virus; and wherein said env gene and said gag-pol gene are under the control of the mH5 promoter.